Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
J&J Pauses COVID-19 Vaccine Trials, Japan PI Too
Johnson & Johnson said on October 12 that it has temporarily paused all clinical trials for its COVID-19 vaccine JNJ-78436735 due to an unexplained illness reported for an overseas participant. A Japan PI study is also subject to this measure,…
To read the full story
Related Article
- Japan Hails Janssen Vaccine Submission as New Option: Spokesman
May 25, 2021
- Janssen Seeks Japan Approval for COVID-19 Vaccine
May 24, 2021
- Janssen Resumes Japan PI for COVID-19 Vaccine after Temporary Pause
November 17, 2020
BUSINESS
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Santen’s Myopia Drug Ryjusea Wins Nod in Philippines
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
- UK Accepts Taletrectinib Filing for ROS1+ NSCLC: Eisai
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…